Genomic Vision

Genomic Vision Liabilities

The The Liabilities of Genomic Vision (GV.PA) as of Oct 22, 2026 is 6.28 M EUR. In the previous year, The Liabilities was 3.70 M EUR — a change of 69.63% (higher).

Liabilities

6.28 MEUR

YoY

69.63%

Last updated:

In 2022, Genomic Vision's total liabilities amounted to 6.28 M EUR, a 69.63% difference from the 3.70 M EUR total liabilities in the previous year.

The Genomic Vision Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2015
3.55 M EUR
Jan 1, 2016
3.18 M EUR
Jan 1, 2017
4.52 M EUR
Jan 1, 2018
4.54 M EUR
Jan 1, 2019
2.38 M EUR
Jan 1, 2020
4.18 M EUR
Jan 1, 2021
3.70 M EUR
Jan 1, 2022
6.28 M EUR
The Genomic Vision Liabilities history
YEARLiabilitiesYoY
6.28 MEUR+69.63%
3.70 MEUR-11.46%
4.18 MEUR+76.00%
2.38 MEUR-47.66%
4.54 MEUR+0.35%
4.52 MEUR+42.07%
3.18 MEUR-10.34%
3.55 MEUR-5.33%
3.75 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genomic Vision Stock analysis

What does Genomic Vision do? Genomic Vision is a biotechnology company that was founded in 2004. It is based in Bagneux, France, and develops and markets innovative molecular diagnostic tools and services based on its patented platform technology. The company's business model is based on collaboration with large pharmaceutical and diagnostic companies to help accelerate their product development and improve their clinical outcomes. Genomic Vision specializes in genetic diagnostics and offers a platform for analyzing DNA structures, allowing for the detection and quantification of genetic changes associated with various diseases such as cancer, neurological disorders, and rare diseases. The company also offers customized solutions and services tailored to the specific needs of its customers. In addition, Genomic Vision licenses its technology and patents to pharmaceutical companies and other organizations. The company has already partnered with Hitachi High-Technologies in Japan to market its platform for cancer monitoring and to develop molecular tests for cancer and other diseases. Genomic Vision has also introduced products such as the FiberVision system for visualizing and analyzing DNA fibers and is working on a new diagnostic test for precise diagnosis of autism and other neurological disorders. The company aims to improve the diagnosis of genetic diseases and advance genomic research. With its patented technology and expertise in molecular diagnostics, Genomic Vision is well positioned to drive the development of new and innovative products. Overall, Genomic Vision is an emerging company focused on the development of molecular diagnostic tools and services, and has a solid foundation in DNA visualization and analysis. With its innovative products and services, the company is well positioned to drive the growth of the molecular diagnostics market and establish itself as a key player in the field. Genomic Vision is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Genomic Vision's Liabilities

Genomic Vision's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Genomic Vision's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Genomic Vision's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Genomic Vision's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Genomic Vision’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Genomic Vision stock

The Liabilities of Genomic Vision is 6.28 M EUR in 2022.

The Liabilities of Genomic Vision changed from 3.70 M EUR to 6.28 M EUR, representing a 69.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Genomic Vision since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Genomic Vision historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Genomic Vision

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genomic Vision